(secondQuint)Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management.

 This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing dextromethorphan and placebo for the treatment of chemotherapy-induced peripheral neuropathy, assessed with a (0-10) numerical scale.

 Cognition, anxiety, depression, sleep and quality of life are also assessed.

 The influence of CYP2D6, CYP3A4 and MDR1 polymorphism on the dextromethorphan analgesic efficacy will be measured.

.

 Dextromethorphan in Chemotherapy-induced Peripheral Neuropathy Management@highlight

The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.

